Study | study type
|
Pathology | T1 | T0 | Patients | sample sizes | ROB | Results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
versus bevacizumab plus carboplatin and paclitaxel | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 | RCT | non squamous - mNSCLC - L1 - Wild Type (WT) | atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) | bevacizumab and caroplatin plus paclitaxel (BCP) | patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy. | 356 / 336 | some concern | conclusif |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 | RCT | non squamous - mNSCLC - L1 - Wild Type (WT) | atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP) | bevacizumab plus carboplatin plus paclitaxel (BCP) | patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy. | 155 / 129 | some concern | conclusif |
|